EichorEICHOR
Study identifier: NCT04135846 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: RecruitingDOXY

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Condition: Alcohol Use Disorder (AUD)  ·  Sponsor: Brown University

PhasePhase 2
Planned participants184
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
WhereProvidence, Rhode Island, United States

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.

This description comes directly from the study's public registry record.

Talk to the study team

Zoe L Brown, BA  ·  401-863-6646  ·  alcohol.stress.study@brown.edu

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Male or female, 18 years of age * Meet the DSM-5 criteria for AUD * Desire to reduce or quit alcohol drinking * Breath alcohol (BrAC) = 0.00 at each visit * In good health as confirmed by medical history, physical examination and lab tests * Willing to adhere to the study procedures * Understand informed consent and questionnaires in English at an 8th grade level Exclusion Criteria: * Women who are breastfeeding or /positive urine test for pregnancy * CrCl\<60mL/min * Suicide attempt in the last three months * Current diagnosis of other substance disorder other than nicotine as assessed by self-report and urine toxicology screen at baseline * Current use of medication that may interact with doxazosin and/or yohimbine * History of allergy to any alpha receptor blockers * Clinical Institute Withdrawal Assessment for Alcohol revised (CIWA-Ar) score ≥ 8 * Treatment with disulfiram, naltrexone, acamprosate, topiramate within 1 month prior to screening * Treatment with any alpha-blocker * Individuals with cardiac heat failure (CHF), as assessed by the medical history, the physical exam and the ECG. * Baseline hypotension defined as BP reading lower than 90/60 mmHg * Use of phosphodiesterase inhibitors (PDE5) erectile dysfunction medication

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (1)

Brown UniversityProvidence, Rhode Island, United StatesRecruiting

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

Providence

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →